Home Microbiology SARS-CoV

SARS-CoV Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
E0613 TC-067533 TC-067533 is a potent SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 of 8.7 μM.
E1111 VV116 VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.
E3159 Caryophylli Flos Extract Caryophylli Flos Extract is drawed from Caryophylli Flos, which exerts inhibitory effects on the wild-type SARS-CoV and HIV/SARS-CoV S pseudovirus infections, showing moderate IC50 inhibitory effects (<100 μg/mL) at 30.3 ± 2.6 μg/mL and 58.8 ± 5.6 μg/mL, respectively. 
E1174 Coronastat(NK01-63) Coronastat(NK01-63) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle.
E1013 Bemnifosbuvir Hemisulfate (AT-527)

Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511, which is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.
S1386 Nafamostat mesilate (FUT-175) Nafamostat mesilate (FUT-175) is a synthetic serine protease inhibitor used as an anticoagulant during hemodialysis. It blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. This compound also attenuates inflammation and apoptosis.
J Immunother Cancer, 2024, 12(11)e009805
Cell Death Dis, 2024, 15(2):109
CNS Neurosci Ther, 2024, 30(6):e14822
Verified customer review of Nafamostat mesilate (FUT-175)
S9731 PF-00835231 PF-00835231 is a 3CLpro (Mpro) inhibitor that may targets SARS-CoV-2 protease 3CLpro as a potential new treatment for COVID-19.
Mol Cell, 2022, S1097-2765(22)00433-6
Bioorg Med Chem Lett, 2022, 66:128732
Nat Commun, 2021, 12(1):6786
S0515 PLpro inhibitor  PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.
PLoS Pathog, 2023, 19(8):e1011592
bioRxiv, 2022, 2022.08.06.503039
S6845 GRL0617 GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. This compound inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.
J Virol, 2024, e0085524.
S3553 Riamilovir Riamilovir (Triazavirin) is a broad-spectrum antiviral drug candidate, which can be used for potential application against the Coronavirus 2019-nCoV.
E0052 Merafloxacin Merafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses.